This study aims to evaluate a new wound treatment called cold atmospheric plasma (CAP) for patients receiving extracorporeal life support (ECLS). Patients on extracorporeal life support (ECLS) often develop wounds at the sites where tubes are inserted, and these wounds can be difficult to heal and prone to infection.
cold atmospheric plasma (CAP) is a gentle, non-heat treatment that can kill bacteria, reduce inflammation, and promote wound healing. In this study, patients will be randomly assigned to receive either standard wound care alone or standard care plus cold atmospheric plasma (CAP) treatment.
Researchers will compare both groups to see whether cold atmospheric plasma (CAP) can reduce infection, improve healing speed, and decrease the need for additional procedures. The study will also monitor safety to ensure the treatment is well tolerated.
The goal is to find a more effective and safe way to improve wound healing in critically ill patients.
Age ≥ 18 years
Receiving extracorporeal life support (ECLS)
Presence of cannulation site wound requiring wound care
Pre-existing severe dermatological conditions at the cannulation site
Severe coagulopathy precluding local intervention
Concurrent receipt of other experimental wound treatments
Life expectancy < 48 hours